Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASMB NASDAQ:CPIX NASDAQ:OMER NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$24.15+3.5%$27.32$16.50▼$39.71$370.77M1.07203,377 shs133,827 shsCPIXCumberland Pharmaceuticals$5.61-1.1%$4.71$1.85▼$6.61$84.95M0.0993,240 shs30,882 shsOMEROmeros$9.64+1.7%$12.10$2.95▼$17.65$686.12M2.521.97 million shs1.42 million shsPCRXPacira BioSciences$22.64-0.8%$23.59$18.80▼$27.64$897.92M0.29411,698 shs342,305 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences-0.04%+2.68%-18.57%-15.23%+35.32%CPIXCumberland Pharmaceuticals+1.25%-0.87%+3.66%+102.50%+3.47%OMEROmeros+1.61%-4.91%-22.61%-13.42%+181.31%PCRXPacira BioSciences+0.35%-1.68%+0.80%+3.63%-6.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASMBAssembly Biosciences$24.15+3.5%$27.32$16.50▼$39.71$370.77M1.07203,377 shs133,827 shsCPIXCumberland Pharmaceuticals$5.61-1.1%$4.71$1.85▼$6.61$84.95M0.0993,240 shs30,882 shsOMEROmeros$9.64+1.7%$12.10$2.95▼$17.65$686.12M2.521.97 million shs1.42 million shsPCRXPacira BioSciences$22.64-0.8%$23.59$18.80▼$27.64$897.92M0.29411,698 shs342,305 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASMBAssembly Biosciences-0.04%+2.68%-18.57%-15.23%+35.32%CPIXCumberland Pharmaceuticals+1.25%-0.87%+3.66%+102.50%+3.47%OMEROmeros+1.61%-4.91%-22.61%-13.42%+181.31%PCRXPacira BioSciences+0.35%-1.68%+0.80%+3.63%-6.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASMBAssembly Biosciences 2.57Moderate Buy$44.0082.19% UpsideCPIXCumberland Pharmaceuticals 1.00SellN/AN/AOMEROmeros 2.83Moderate Buy$40.33318.40% UpsidePCRXPacira BioSciences 2.29Hold$29.4029.86% UpsideCurrent Analyst Ratings BreakdownLatest ASMB, PCRX, OMER, and CPIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026ASMBAssembly Biosciences MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$40.00 ➝ $45.006/10/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/2/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/28/2026ASMBAssembly Biosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$43.005/20/2026PCRXPacira BioSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D) ➝ Sell (D+)5/14/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D-) ➝ Hold (C-)5/14/2026OMEROmeros HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.005/4/2026ASMBAssembly Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$50.005/1/2026PCRXPacira BioSciences Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$22.00 ➝ $24.005/1/2026PCRXPacira BioSciences Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $32.004/21/2026OMEROmeros Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASMBAssembly Biosciences$72.30M5.31N/AN/A$13.04 per share1.85CPIXCumberland Pharmaceuticals$44.52M1.89$0.36 per share15.46$1.64 per share3.42OMEROmerosN/AN/A$1.90 per share5.07($1.71) per shareN/APCRXPacira BioSciences$726.41M1.23$3.82 per share5.92$16.11 per share1.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASMBAssembly Biosciences-$6.12M-$0.11N/AN/AN/A-8.98%-4.21%-3.14%8/5/2026 (Estimated)CPIXCumberland Pharmaceuticals-$2.84M-$0.49N/AN/AN/A-17.60%-12.01%-4.24%8/11/2026 (Estimated)OMEROmeros-$3.35M$0.7013.7730.13N/AN/A-102.16%64.87%8/13/2026 (Estimated)PCRXPacira BioSciences$7.03M$0.12188.688.48N/A0.70%10.24%5.47%8/4/2026 (Estimated)Latest ASMB, PCRX, OMER, and CPIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026OMEROmeros-$0.40-$0.24+$0.16$0.62$4.19 million$9.89 million5/7/2026Q1 2026ASMBAssembly Biosciences-$0.65-$0.54+$0.11-$0.54$9.27 million$8.21 million5/5/2026Q1 2026CPIXCumberland Pharmaceuticals-$0.13-$0.13N/A-$0.22$8.50 million$9.13 million4/30/2026Q1 2026PCRXPacira BioSciences$0.61$0.60-$0.01$0.07$171.80 million$177.38 million3/31/2026Q4 2025OMEROmeros-$0.55$3.14+$3.69$0.98$40.15 millionN/A3/19/2026Q4 2025ASMBAssembly Biosciences-$0.51$2.48+$2.99$2.48$7.42 million$42.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthASMBAssembly BiosciencesN/AN/AN/AN/AN/ACPIXCumberland PharmaceuticalsN/AN/AN/AN/AN/AOMEROmerosN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASMBAssembly BiosciencesN/A6.656.65CPIXCumberland Pharmaceuticals0.250.950.79OMEROmerosN/A3.033.03PCRXPacira BioSciences0.564.733.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASMBAssembly Biosciences19.92%CPIXCumberland Pharmaceuticals15.51%OMEROmeros48.79%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipASMBAssembly Biosciences5.30%CPIXCumberland Pharmaceuticals42.07%OMEROmeros10.50%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASMBAssembly Biosciences10015.89 million15.05 millionOptionableCPIXCumberland Pharmaceuticals8014.98 million8.68 millionOptionableOMEROmeros21072.38 million64.78 millionOptionablePCRXPacira BioSciences72039.35 million36.83 millionOptionableASMB, PCRX, OMER, and CPIX HeadlinesRecent News About These CompaniesRice Hall James & Associates LLC Decreases Stock Holdings in Pacira BioSciences, Inc. $PCRXJune 16 at 8:46 AM | marketbeat.comPacira BioSciences (NASDAQ:PCRX) SVP Lauren Riker Sells 6,115 SharesJune 13, 2026 | insidertrades.comGagnon Securities LLC Acquires 51,494 Shares of Pacira BioSciences, Inc. $PCRXJune 13, 2026 | marketbeat.comGagnon Advisors LLC Has $6.75 Million Position in Pacira BioSciences, Inc. $PCRXJune 13, 2026 | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Stock Crosses Below 50 Day Moving Average - Should You Sell?June 12, 2026 | marketbeat.comPacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual MeetingJune 9, 2026 | prnewswire.comPacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.comPacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual MeetingJune 4, 2026 | prnewswire.comPacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director NomineesJune 1, 2026 | prnewswire.comPharmaCorp Rx Inc. Announces First Quarter 2026 Financial ResultsJune 1, 2026 | globenewswire.comPacira BioSciences, Inc. $PCRX Stock Position Lifted by Intech Investment Management LLCJune 1, 2026 | marketbeat.comHillsdale Investment Management Inc. Buys Shares of 308,200 Pacira BioSciences, Inc. $PCRXMay 30, 2026 | marketbeat.comConsidering Pacira Biosciences Inc (PCRX) Stock After Q1 Report? Check the DetailsMay 29, 2026 | uk.finance.yahoo.comPacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company’s Strategic Direction and Highly Qualified NomineesMay 29, 2026 | finance.yahoo.comLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote âFORâ All of Paciraâs Director Nominees May 28, 2026 | markets.businessinsider.comLeading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira's Director NomineesMay 28, 2026 | globenewswire.comDOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTIONMay 28, 2026 | prnewswire.comPacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified NomineesMay 27, 2026 | globenewswire.comPacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder ArthroplastyMay 27, 2026 | globenewswire.comPacira BioSciences Sets the Record Straight Regarding DOMA’s Misleading Statements About Pacira’s Intellectual Property StrategyMay 26, 2026 | markets.businessinsider.comPacira BioSciences Sets the Record Straight Regarding DOMA's Misleading Statements About Pacira's Intellectual Property StrategyMay 26, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesPalantir and Dell Build an AI OS for the ParanoidBy Chris Markoch | May 24, 2026Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised GuidanceBy Thomas Hughes | June 1, 2026AirJoule Technologies: A Cool Shot at a MultibaggerBy Thomas Hughes | June 9, 2026Fifth Third’s Big Bet Is OnBy Peter Frank | June 4, 2026The 127-Gigawatt Problem: Why AI Needs Its Own PowerBy Jeffrey Neal Johnson | June 12, 2026ASMB, PCRX, OMER, and CPIX Company DescriptionsAssembly Biosciences NASDAQ:ASMB$24.15 +0.82 (+3.51%) Closing price 04:00 PM EasternExtended Trading$24.10 -0.04 (-0.19%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.Cumberland Pharmaceuticals NASDAQ:CPIX$5.61 -0.06 (-1.06%) Closing price 04:00 PM EasternExtended Trading$5.51 -0.10 (-1.71%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Omeros NASDAQ:OMER$9.64 +0.16 (+1.69%) Closing price 04:00 PM EasternExtended Trading$9.72 +0.08 (+0.82%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.Pacira BioSciences NASDAQ:PCRX$22.64 -0.18 (-0.79%) Closing price 04:00 PM EasternExtended Trading$22.64 +0.00 (+0.02%) As of 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave Insider Sales Look Big, But Should Investors Worry? Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves Meta and Cloud Computing: Real Potential, or a Shot in the Dark? Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Fox Captures The Living Room With $22B Roku Buy Dave & Buster’s Q1 Miss Raises the Stakes for Its Turnaround Plan Microsoft’s Xbox Problem Is Bigger Than a Console War Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
